# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst Michael Freeman initiates coverage on Bausch Health Companies (NYSE:BHC) with a Market Perform rating ...
This lawsuit was filed in connection with the Notice of Paragraph IV Certification, dated May 10, 2024, received from Norwich a...
Bausch Health understands that such a lawsuit would automatically preclude the FDA from approving Norwich's ANDA for up to ...
Bausch Health misses Q1 EPS estimates at 59 cents, despite a revenue increase of 11%.
Bausch Health Companies (NYSE:BHC) reported quarterly sales of $2.153 which missed the analyst consensus estimate of $2.156 bil...